Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

ASPIRA PATHLAB & DIAGNOSTICS LTD.

NSE : NABSE : 540788ISIN CODE : INE500C01017Industry : Hospital & Healthcare ServicesHouse : Private

BSE59.22-3.08 (-4.94 %)

PREV CLOSE ( ) 62.30

OPEN PRICE ( ) 59.19

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 586

TODAY'S LOW / HIGH ( )59.19 64.00

52 WK LOW / HIGH ( ) 25106.78

NSE

This Company is not listed in NSE

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 03-07 1973

Management Info

Haseeb Drabu - Chairman Pankaj Shah - Managing Director

Registered Office

Address Flat No. 2, R D Shah Building,Shraddanand Road, Opp. Ghatkopar Railway Station,Ghatkopar (West),
Mumbai,
Maharashtra-400086

Phone 022-7197 5756 / 2513 9090

Email info@aspiradiagnostics.com / support@aspiradiagnostics.com

Website www.aspiradiagnostics.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,L B S Marg,Vikhroli (West),Mumbai

Listing : BSE

NEWS

22Apr Aspira Pathlab & Diagnostics informs
In continuation to earlier intimation dated January 02, 2025 regarding i..

04Sep Aspira Pathlab & Diagnostics informs a
Aspira Pathlab & Diagnostics has enclosed copies of Newspaper advert..

24Aug Aspira Pathlab & Diagnostics informs a
Aspira Pathlab & Diagnostics has informed that 51st Annual General M..

24Aug Aspira Pathlab & Diagnostics informs a
Aspira Pathlab & Diagnostics has informed that as per the Ministry o..

09Apr Aspira Pathlab & Diagnostics informs a
Aspira Pathlab & Diagnostics has confirmed that Aspira Pathlab &..

Financials

Rs. in Millions

	QTR Dec 24	ANNUAL 24
Net Profit	3.76	-26.73
Gross Profit	3.76	-26.73
Operating Profit	8.56	-7.66
Net Sales	54.07	132.05

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr Agarwals Eye Hsp (BSE) 4000.85 (1.05%)	M.Cap ( in Cr)1880.40
Thyrocare Tech. (BSE) 939.65 (3.53%)	M.Cap ( in Cr)4979.53
Max Healthcare Inst (BSE) 1126.95 (1.50%)	M.Cap ( in Cr)109555.55
Metropolis Health. (BSE) 1667.15 (0.39%)	M.Cap ( in Cr)8549.64
RainbowChildrenS Med (BSE) 1346.45 (0.47%)	M.Cap ( in Cr)13673.43

Shareholding Pattern

	NON-INSTITUTION	81.61%
	PROMOTERS	18.39%
	MUTUAL FUNDS/UTI	0%
	FI/BANKS/INSURANCE	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
No Data Found

Risk Disclosures on Derivatives

Smart Quotes

ASPIRA PATHLAB & DIAGNOSTICS LTD.